Biopharma companies develop medicines, vaccines and advanced therapies to prevent, treat and manage disease. The sector spans drug discovery, clinical development, manufacturing and commercialisation across a wide range of therapeutic areas.
This category includes companies working on:
Browse 304 UK biopharma companies below.
Antibody therapies depleting pathogenic T cells for autoimmune disease cure
Re-Aim Therapeutics is a biotechnology company developing antibody-based therapies designed to achieve functional cures for T cell-mediated autoimmune diseases. The company's approach selectively depletes pathogenic T cell subsets that drive chronic inflammation, using precise targeting of disease-relevant membrane…
Antibody therapy to deplete amyloid deposits in ATTR cardiomyopathy
Immutrin is a biotechnology company developing an engineered antibody therapeutic designed to actively remove amyloid deposits from tissues in patients with amyloidosis. Its lead asset targets ATTR cardiomyopathy, a progressive and often fatal cardiac disease caused by transthyretin amyloid accumulation, for which no…
Synthetic plant metabolites for osteoarthritis and age-related disease
AKL Therapeutics is a privately held UK pharmaceutical company developing APPA, a patented oral investigational medicine combining two synthetic plant metabolites that act synergistically to target multiple signalling pathways in osteoarthritis. Animal studies have demonstrated pain reduction and delayed cartilage…
mRNA vaccine manufacturer and R&D partner
Moderna is a company developing and manufacturing mRNA-based medicines and vaccines across infectious disease, oncology and rare disease. Its UK Innovation and Technology Centre, opened at Harwell in September 2025, is the first facility in the UK capable of onshore mRNA vaccine manufacturing, with capacity for up to…
Autophagy-enhancing small molecule drugs for neurodegeneration and rare disease
Samsara Therapeutics is a drug discovery company developing first-in-class small molecule therapeutics that restore autophagy, the cellular process of degrading and recycling damaged proteins, which declines with age and is dysfunctional in multiple diseases. Its platform identifies and chemically optimises…
Clinical-stage peptide therapeutics for autoimmune and infectious disease
ImmuPharma is a clinical-stage biopharmaceutical company developing peptide-based therapeutics and precision diagnostics for autoimmune disease, infectious disease and metabolic disorders. Its lead candidate, a first-in-class immunormalizer for lupus, has completed a Phase III pivotal trial, aiming to restore normal…
Hypoxia-activated CAR-T cell therapy platform for solid tumour cancers
Korecyte Bio is a preclinical-stage cell therapy company developing HypoxiCAR, a modular CAR-T platform for treating solid tumours. The technology uses a dual-sensor genetic switch that keeps engineered T-cells dormant in healthy tissue and activates them only within the low-oxygen environment typical of solid…
Cyclic peptide screening platform for first-in-class cancer drugs
Curve Therapeutics is a drug discovery company using its proprietary platform to identify first-in-class small molecule therapeutics against targets that have been difficult to address using conventional methods. The platform screens gene-encoded cyclic peptide libraries inside mammalian cells to identify functionally…
Oncolytic virus platform for tumour-targeted cancer immunotherapy
Accession Therapeutics is a clinical-stage biotechnology company developing tumour-targeted immunotherapies based on its proprietary oncolytic virus platform. Designed for systemic delivery, the platform selectively replicates within cancer cells to generate therapeutic payloads locally at the tumour site. The…
LNP-mRNA growth factor therapy to restore hearing loss
CamGene Therapeutics is a preclinical biotechnology company developing lipid nanoparticle-delivered mRNA medicines to treat hearing loss at its underlying cellular cause. Its lead approach uses an LNP-mRNA growth factor therapeutic designed to regenerate cochlear nerve cells and reduce inflammation, aiming to restore…
AI-driven target discovery from human tissue omics
Relation is a platform biotechnology company integrating machine learning with single-cell and spatial multi-omics data derived directly from patient tissue to discover and validate novel drug targets. Its initial research focus is bone biology, with a proprietary observational study generating deeply characterised…
Preclinical small-molecule therapeutics targeting a novel pathway in chronic pain
Sevenless Therapeutics is a preclinical biotechnology company developing small-molecule medicines for people with chronic pain that responds poorly to existing treatments. The company has identified a new target in pain signalling using computational and mathematical modelling approaches and is designing small…
European hub for RNAi therapeutics developer
Alnylam UK is the European operational headquarters of Alnylam Pharmaceuticals, the pioneer of RNA interference therapeutics. Based in Maidenhead, the UK office serves as Alnylam's primary base for European commercial operations, medical affairs, and regulatory activities. Alnylam has six approved RNAi medicines on…
Culturing microbial dark matter to discover novel antimicrobials and bioactives
Bactobio is a biotechnology company using synthetic biology, next-generation sequencing, and machine learning to culture the vast majority of environmental microbes that have previously been unculturable. Access to this largely unexplored bioresource enables systematic discovery of novel antimicrobial compounds and…
Plasma fractionation and manufacture of plasma-derived therapies
Kedrion Biopharma is a biopharmaceutical manufacturer specialising in the fractionation of human blood plasma to produce albumin solutions, immunoglobulins and coagulation factors for the treatment of rare and life-threatening conditions including immunodeficiencies and bleeding disorders. Operating from a 130,000…
Specialty biopharma covering oncology, neurology, and fertility
Merck Serono Limited is the UK commercial subsidiary of Merck KGaA's Healthcare division, a German science and technology company founded in 1668. The UK operation markets prescription medicines across oncology, neurology, immunology, endocrinology, and fertility. Key products include Erbitux for colorectal and…
Specialist renal pharmaceuticals and clinical nutrition products
Stanningley Pharma is a specialty pharmaceutical company focused on products for patients with chronic kidney disease and other hospital medicine therapeutic areas. The company licenses, develops, and markets prescription medicines and Foods for Special Medical Purposes into the NHS, including a calcium acetate…
Native mass spectrometry platform for small molecule drug discovery
OMass Therapeutics is a biotechnology company developing small molecule therapeutics against membrane proteins, GPCRs, and intracellular complexes that have historically been difficult to drug. Its proprietary platform combines native mass spectrometry, novel biochemistry, and custom chemistry to interrogate protein…
AI-driven precision therapeutics for metabolic syndrome diseases
Multiomic Health is a data-centric therapeutics company developing precision medicines for metabolic syndrome-related conditions, including type 2 diabetes, cardiovascular disease, chronic kidney disease and non-alcoholic fatty liver disease. The company integrates multi-omics data with longitudinal clinical datasets…
Immuno-oncology target discovery and antibody therapeutics developer
4C Biomed is a biotechnology company developing immuno-oncology therapies and target discovery platforms based on patient-derived tumour and immune cell systems. The company uses integrated screening technologies and clinical data to identify novel immune targets and develop antibody therapeutics designed to enhance…